Viking Therapeutics Inc (VKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has a cash flow conversion efficiency ratio of -0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-85.29 Million) by net assets ($639.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Viking Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Viking Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Viking Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viking Therapeutics Inc ranked by their cash flow conversion efficiency. Explore VKTX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wendel
PA:MF
|
0.079x |
|
Simmons First National Corporation
NASDAQ:SFNC
|
0.042x |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
-0.048x |
|
Eurazeo
PA:RF
|
-0.021x |
|
Beijing GeoEnviron Engineering
SHG:603588
|
0.003x |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
-0.020x |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
-0.041x |
|
Gentera S.A.B. de C.V
MX:GENTERA
|
0.037x |
Annual Cash Flow Conversion Efficiency for Viking Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Viking Therapeutics Inc from 2013 to 2025. View VKTX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $639.06 Million | $-87.79 Million | -0.137x | -37.75% |
| 2024-12-31 | $880.28 Million | $-87.79 Million | -0.100x | +52.64% |
| 2023-12-31 | $348.42 Million | $-73.38 Million | -0.211x | +36.76% |
| 2022-12-31 | $145.32 Million | $-48.40 Million | -0.333x | -41.29% |
| 2021-12-31 | $201.88 Million | $-47.59 Million | -0.236x | -164.47% |
| 2020-12-31 | $244.34 Million | $-21.78 Million | -0.089x | +0.22% |
| 2019-12-31 | $277.12 Million | $-24.75 Million | -0.089x | -41.80% |
| 2018-12-31 | $297.75 Million | $-18.75 Million | -0.063x | +94.25% |
| 2017-12-31 | $13.46 Million | $-14.76 Million | -1.096x | +20.38% |
| 2016-12-31 | $8.04 Million | $-11.07 Million | -1.377x | -37.55% |
| 2015-12-31 | $8.72 Million | $-8.73 Million | -1.001x | -1491.52% |
| 2014-12-31 | $-22.13 Million | $-1.59 Million | 0.072x | -76.96% |
| 2013-12-31 | $-250.60K | $-78.23K | 0.312x | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more